14 completed, 8 recruiting, 3 terminated, 2 active not recruiting. 12 Phase 2, 6 Phase 1, 6 Phase 3, 3 Not applicable.
Follow Glomerulonephritis, Membranoproliferative: new trials by email Literature Review of Glomerulonephritis, Membranoproliferative trials Research Report on Glomerulonephritis, Membranoproliferative
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Complement 3 Glomerulopathy (C3G) Patients Treated With Iptacopan Through an Early Access Program in Spain Complement 3 Glomerulopathy | Recruiting | Novartis Pharmaceuticals | 35 | 2026-09-22 | 2026-10-07 | |
| A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy Paroxysmal Nocturnal Hemoglobinuria, C3 Glomerulopathy | Recruiting | Novartis Pharmaceuticals | 21 | 2026-06-15 | 2026-06-26 | |
| Chinese Adults With Kidney Disease ADX-038, Telitacicept - Immunoglobulin A Nephropathy (IgAN), Complement 3 Glomerulopathy (C3G) | Phase 2 | Recruiting | ADARx Pharmaceuticals, Inc. | 30 | 2026-05-21 | 2026-09-03 |
| Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS Iptcaopan 200 mg - Atypical Hemolytic Uremic Syndrome | Phase 3 | Recruiting | Novartis Pharmaceuticals | 65 | 2024-05-08 | 2026-06-04 |
| Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare Diseases Skin biopsy - Atypical Hemolytic Uremic Syndrome, Membranoproliferative Glomerulonephritis | Not applicable | Recruiting | Mario Negri Institute for Pharmacological Research | 105 | 2024-02-21 | 2026-03-23 |
| New Analytic Tools for aHUS and C3G Diagnosis C3NEF assay - Hemolytic-Uremic Syndrome, Membranoproliferative Glomerulonephritis | Not applicable | Active not recruiting | Mario Negri Institute for Pharmacological Research | 180 | 2023-07-01 | 2026-03-23 |
| An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis Pegcetacoplan - C3G, IC-MPGN | Phase 3 | Active not recruiting | Apellis Pharmaceuticals, Inc. | 100 | 2023-05-29 | 2026-04-02 |
| Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria ALXN1720 - Proteinuria | Phase 1 | Completed | Alexion Pharmaceuticals, Inc. | 13 | 2022-06-29 | 2023-06-29 |
| Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN) BCX9930 - Complement 3 Glomerulopathy, Immunoglobulin A Nephropathy | Phase 2 | Terminated | BioCryst Pharmaceuticals | 2 | 2022-02-18 | 2024-05-02 |
| Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis Pegcetacoplan, Placebo - C3G, IC-MPGN | Phase 3 | Completed | Apellis Pharmaceuticals, Inc. | 124 | 2021-11-12 | 2026-01-29 |
| Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN Pegcetacoplan - C3G, IC-MPGN | Phase 2 | Completed | Apellis Pharmaceuticals, Inc. | 13 | 2021-09-07 | 2026-04-21 |
| Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy Aliskiren, Enalapril - C3 Glomerulopathy, Membranoproliferative Glomerulonephritis | Phase 2 | Recruiting | Region Skane | 30 | 2020-10-01 | 2025-06-22 |
| Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN LNP023 - C3 Glomerulopathy, Immune-complex-membranoproliferative Glomerulonephritis | Phase 3 | Recruiting | Novartis Pharmaceuticals | 225 | 2019-10-03 | 2026-08-07 |
| Non-contrast Enhanced MRI in Patients With C3 Glomerulopathy (C3G) or Immune-complex Membranoproliferative Glomerulonephritis (IC-MPGN) Enrolled in the ACH471-205 Study Non contrast-enhanced magnetic resonance imaging - C3 Glomerulonephritis, C3 Glomerulopathy | Not applicable | Completed | Mario Negri Institute for Pharmacological Research | 7 | 2018-12-06 | 2021-11-26 |
| Synergetic B-cell Immunomodulation in SLE - 2nd Study. Belimumab Injection - Lupus Erythematosus, Systemic | Phase 3 | Completed | Leiden University Medical Center | 71 | 2018-10-01 | 2026-10-07 |
| A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471 Danicopan - C3 Glomerulonephritis, C3 Glomerulopathy | Phase 2 | Terminated | Alexion Pharmaceuticals, Inc. | 22 | 2018-06-20 | 2023-08-21 |
| A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G) Danicopan, Placebo - C3 Glomerulopathy, C3 Glomerulonephritis | Phase 2 | Completed | Alexion Pharmaceuticals, Inc. | 13 | 2018-06-12 | 2022-10-14 |
| Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies APL-2 - IgA Nephropathy, Lupus Nephritis | Phase 2 | Completed | Apellis Pharmaceuticals, Inc. | 21 | 2018-02-26 | 2025-02-13 |
| Controlled Trial Evaluating Avacopan in C3 Glomerulopathy Avacopan, Avacopan Matching Placebo - C3 Glomerulopathy (C3G) | Phase 2 | Completed | Amgen | 57 | 2017-09-29 | 2025-03-13 |
| Daratumumab in Treatment of PGNMID and C3 GN Daratumumab - Membranoproliferative Glomerulonephritis | Phase 2 | Completed | Fernando Fervenza | 12 | 2017-09-07 | 2022-08-31 |
Showing 20 of 31. Sign in to see all of them.
Glomerulonephritis, IGA (5) · Lupus Nephritis (4) · Atypical Hemolytic Uremic Syndrome (3) · Glomerulonephritis, Membranous (3) · Proteinuria (3) · Glomerulosclerosis, Focal Segmental (2) · Hematuria, Benign Familial (2) · Nephrosis, Lipoid (2) · Nephrotic Syndrome (2) · Polycystic Kidney, Autosomal Dominant (2) · Adenine phosphoribosyltransferase deficiency (1) · Autoimmune Diseases (1) · Bartter Syndrome (1) · Calciphylaxis (1)
Female Urogenital Diseases (31) · Female Urogenital Diseases and Pregnancy Complications (31) · Immune System Diseases (31) · Kidney Diseases (31) · Male Urogenital Diseases (31) · Nephritis (31) · Urogenital Diseases (31) · Urologic Diseases (31) · Glomerulonephritis (30) · Autoimmune Diseases (6) · Anemia (5) · Anemia, Hemolytic (5) · Connective Tissue Diseases (5) · Hematologic Diseases (5) · Hemic and Lymphatic Diseases (5)
pegcetacoplan (4) · danicopan (3) · Rituximab (2) · eculizumab (2) · Cyclosporine (1) · Enalapril (1) · aliskiren (1) · avacopan (1) · belimumab (1) · daratumumab (1) · glucuronyl glucosamine glycan sulfate (1) · iptacopan (1) · rhoA GTP-Binding Protein (1) · telitacicept (1)
Apellis Pharmaceuticals, Inc. (5) · Alexion Pharmaceuticals, Inc. (4) · Mario Negri Institute for Pharmacological Research (4) · Novartis Pharmaceuticals (4) · University of Iowa (2) · ADARx Pharmaceuticals, Inc. (1) · Amgen (1) · Assiut University (1) · BioCryst Pharmaceuticals (1) · Celldex Therapeutics (1) · Columbia University (1) · Fernando Fervenza (1) · Leiden University Medical Center (1) · Mayo Clinic (1) · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (1)
United States (15) · Italy (11) · Netherlands (8) · United Kingdom (8) · Spain (7) · France (6) · Australia (5) · Belgium (5) · Brazil (5) · Argentina (4) · Czechia (4) · Japan (4) · South Korea (4) · Switzerland (4) · Canada (3)
Marina Noris, PhD (2) · Richard JH Smith, MD (2) · Arezoo Mirad (1) · Carla M Nester, MD, MSA, FASN (1) · Carla Nester, MD, MSA (1) · Diana Karpman (1) · Fernando C Fervenza, MD (1) · Gerald B Appel, MD (1) · John J. Dillon, M.D., M.S. (1) · Richard Smith, MD (1)
PMID 36423588, PMID 42133432, PMID 22403278, PMID 33685975, PMID 36371234, PMID 37036696, PMID 37926085, PMID 38775637, PMID 39392695, PMID 39899371, PMID 41337715, PMID 41805697
2017 (2), 2023 (2), 2016 (1), 2018 (1), 2019 (1)